|Bid||17.90 x 500|
|Ask||28.25 x 100|
|Day's Range||18.00 - 19.50|
|52 Week Range||9.05 - 24.00|
|PE Ratio (TTM)||-6.15|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||28.25|
Investors in Versartis, Inc. (VSAR) need to pay close attention to the stock based on moves in the options market lately.
MENLO PARK, Calif., June 01, 2017-- Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone for growth ...
Levi & Korsinsky, LLP announces it has commenced an investigation of Versartis Inc. concerning possible breaches of fiduciary duty. To obtain additional informati